Literature DB >> 27624470

Genetic landscape of meningioma.

Sayaka Yuzawa1,2, Hiroshi Nishihara3,4, Shinya Tanaka5,3.   

Abstract

Meningioma is the most common intracranial tumor, arising from arachnoid cells of the meninges. Monosomy 22 and inactivating mutations of NF2 are well-known genetic alterations of meningiomas. More recently, mutations in TRAF7, AKT1, KLF4, SMO, and PIK3CA were identified by next-generation sequencing. We here reviewed 553 meningiomas for the mutational patterns of the six genes. NF2 aberration was observed in 55 % of meningiomas. Mutations of TRAF7, AKT1, KLF4, PIK3CA, and SMO were identified in 20, 9, 9, 4.5, and 3 % of cases, respectively. Altogether, 80 % of cases harbored at least one of the genetic alterations in these genes. NF2 alterations and mutations of the other genes were mutually exclusive with a few exceptions. Clinicopathologically, tumors with mutations in TRAF7/AKT1 and SMO shared specific features: they were located in the anterior fossa, median middle fossa, or anterior calvarium, and most of them were meningothelial or transitional meningiomas. TRAF7/KLF4 type meningiomas showed different characteristics in that they occurred in the lateral middle fossa and median posterior fossa as well as anterior fossa and median middle fossa, and contained a secretory meningioma component. We also discuss the mutational hotspots of these genes and other genetic/cytogenetic alterations contributing to tumorigenesis or progression of meningiomas.

Entities:  

Keywords:  Genetics; Meningioma; Next-generation sequencers

Mesh:

Substances:

Year:  2016        PMID: 27624470     DOI: 10.1007/s10014-016-0271-7

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  40 in total

1.  SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.

Authors:  Julien Boetto; Franck Bielle; Marc Sanson; Matthieu Peyre; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

2.  Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.

Authors:  Richard G Everson; Yuuri Hashimoto; Jacob L Freeman; Tiffany R Hodges; Jason Huse; Shouhao Zhou; Joanne Xiu; David Spetzler; Nader Sanai; Lyndon Kim; Santosh Kesari; Andrew Brenner; Franco De Monte; Amy Heimberger; Shaan M Raza
Journal:  J Neurooncol       Date:  2018-05-30       Impact factor: 4.130

3.  Cellular prion protein (PrPC) in the development of Merlin-deficient tumours.

Authors:  L Provenzano; Y Ryan; D A Hilton; J Lyons-Rimmer; F Dave; E A Maze; C L Adams; R Rigby-Jones; S Ammoun; C O Hanemann
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

4.  Female gender and exogenous progesterone exposition as risk factors for spheno-orbital meningiomas.

Authors:  Caroline Apra; Paul Roblot; Abdu Alkhayri; Caroline Le Guérinel; Marc Polivka; Dorian Chauvet
Journal:  J Neurooncol       Date:  2020-07-23       Impact factor: 4.130

5.  Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma.

Authors:  Dustin T Proctor; Zeel Patel; Sanju Lama; Lothar Resch; Guido van Marle; Garnette R Sutherland
Journal:  Oncoimmunology       Date:  2018-09-05       Impact factor: 8.110

6.  Clinical and histopathological predictors of outcome in malignant meningioma.

Authors:  Andrea D Maier; Jiri Bartek; Frank Eriksson; Heidi Ugleholdt; Marianne Juhler; Helle Broholm; Tiit I Mathiesen
Journal:  Neurosurg Rev       Date:  2019-03-13       Impact factor: 3.042

7.  Landscape of genetic variants in sporadic meningiomas captured with clinical genomics.

Authors:  Nathan K Leclair; Erica Shen; Qian Wu; Leo Wolansky; Kevin Becker; Lei Li; Ketan R Bulsara
Journal:  Acta Neurochir (Wien)       Date:  2022-07-26       Impact factor: 2.816

8.  P53 Suppressor Gene Tissue Microarray-based Protein Expression Analysis in Meningiomas.

Authors:  Dimitrios Roukas; Anastasios Kouzoupis; Despoina Spyropoulou; George Papanastasiou; Evangelos Tsiambas; George Tsouvelas; Evangelos Falidas; Vasileios Ragos; Dimitrios Peschos; Loukas Manaios; Spyros Katsinis; Arezina Manoli; Sotirios Papouliakos; Andreas C Lazaris; Nikolaos Kavantzas
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

9.  Molecular and translational advances in meningiomas.

Authors:  Suganth Suppiah; Farshad Nassiri; Wenya Linda Bi; Ian F Dunn; Clemens Oliver Hanemann; Craig M Horbinski; Rintaro Hashizume; Charles David James; Christian Mawrin; Houtan Noushmehr; Arie Perry; Felix Sahm; Andrew Sloan; Andreas Von Deimling; Patrick Y Wen; Kenneth Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

10.  A description of familial clustering of meningiomas in the Utah population.

Authors:  William T Couldwell; Lisa A Cannon-Albright
Journal:  Neuro Oncol       Date:  2017-11-29       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.